Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 13/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31129758 | 0.98 | IKZF2 (0.56) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129495 | 0.95 | IKZF2 (0.55) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL22581128 | 0.92 | IKZF2 (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL30023739 | 0.92 | IKZF2 (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL20234415 | 0.91 | CRBN (0.51) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129674 | 0.91 | IKZF2 (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129681 | 0.90 | IKZF2 (0.49) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129642 | 0.89 | IKZF2 (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL25133940 | 0.88 | IKZF2 (0.50) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL29132146 | 0.88 | IKZF2 (0.50) | IKZF2IKZF1CRBNIKZF3DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485735-B2 | Selective CDK4/6 inhibitor and preparation thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2022-11-01 | — | — | US | disclosed |
| US-20200339572-A1 | NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20200339572-A1 | NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485735-B2 | Selective CDK4/6 inhibitor and preparation thereof | CDK4, CDK6, CDK3 | IKZF2 1839/4885IKZF1 1337/4885CRBN 835/4885 |
| US-20200339572-A1 | NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF | CDK4, CDK6, CCNI | IKZF2 3515/4885IKZF1 2441/4885CRBN 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.